^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BMC128

i
Other names: BMC128, BMC-128, BMC 128
Associations
Trials
Company:
Evogene
Drug class:
Microbiome modulator
Associations
Trials
10ms
BMC128-001: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Biomica Ltd. | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR wild-type • ALK wild-type
|
Opdivo (nivolumab) • BMC128
over1year
BMC128-001: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (clinicaltrials.gov)
P1, N=12, Recruiting, Biomica Ltd. | Trial completion date: May 2023 --> Nov 2025 | Trial primary completion date: Feb 2023 --> Apr 2024
Trial completion date • Trial primary completion date • Combination therapy
|
EGFR wild-type • ALK wild-type
|
Opdivo (nivolumab) • BMC128